Operating CF
$14.3B
Capex
-$6.24B
Free Cash Flow
$8.07B
FCF Margin
+56.4%
Cash flow waterfall for AstraZeneca (AZN) — TTM through Q1 2026
Free cash flow: $8.07B
Cash flow breakdown for AstraZeneca (AZN) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Operating Cash Flow | $14.3B | $14.3B |
| Capital Expenditure | -$6.24B | $8.07B |
| Free Cash Flow | $8.07B | $8.07B |
| Acquisitions | -$1.14B | $6.92B |
| Other Investing | -$36.9M | $6.89B |
| Dividends Paid | -$4.89B | $2B |
| Net Debt Change | $1.38B | $3.38B |
| Other Financing & FX | -$1.1B | $2.28B |
| Net Cash Increase | $2.28B | $2.28B |
- Operating Cash Flow$14.3B
- Capital Expenditure-$6.24B
- Free Cash Flow$8.07B
- Acquisitions-$1.14B
- Other Investing-$36.9M
- Dividends Paid-$4.89B
- Net Debt Change$1.38B
- Other Financing & FX-$1.1B
- Net Cash Increase$2.28B
Want to see what drove the FCF change?Free Cash Flow Bridge
Frequently asked questions
Data & methodology
AstraZeneca (AZN) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Cash Flow
Forecast & Valuation
Operations
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement
Capital Return
- Buybacks0.14% TTM
- Dividend Profile1.89% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History3 splits
How this company returns cash to shareholders — buybacks, dividends, and stock splits.